查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751231

靜脈鐵市場規模、佔有率、趨勢分析報告：依產品、應用、地區、細分市場、預測，2025 年至 2030 年

Intravenous Iron Drugs Market Size, Share, & Trends Analysis Report By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), By Application (Chronic Kidney Disease), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

靜脈注射鐵市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球靜脈注射鐵市場規模預計到2030年將達到56.2億美元，2025年至2030年期間的複合年成長率為9.1%。

預計預測期內，產業競爭將維持在高水準。跨國公司佔據了市場的大部分收益佔有率。此外，成長機會吸引了新的參與者，進一步加劇了競爭對手之間的競爭。市場分散，主要企業正在採取一系列成長策略，例如策略聯盟、收購和新藥上市，以搶佔更大的市場佔有率。

感染疾病帶來的沉重疾病負擔，加上營養不良，是該地區兒童貧血的主要原因之一。新冠疫情也導致重症患者貧血增多，在某些情況下甚至導致缺氧，進一步增加了全球對治療貧血的鐵補充劑的需求。

貧血盛行率的上升也歸因於各種婦科和胃腸道疾病，這推動了靜脈注射療法在世界各地的普及。例如，同年齡層非孕婦貧血的總體盛行率為29.6%，孕婦貧血的盛行率為36.5%。由於醫療保健預算和投資的增加，預計預測期內市場將大幅成長。

口服鐵補充劑的缺點包括消化器官系統問題，例​​如胃痛、便秘、食慾不振、噁心和嘔吐，因此患者更傾向於靜脈注射。靜脈注射鐵補充劑已被證明可以改善體內鐵的吸收，促進促紅血球生成素促效劑 (ESA) 的分泌，並改善貧血。其他益處包括改善心臟健康，並且適用於透析患者，尤其是正在接受血液透析機的患者。

靜脈注射鐵市場報告重點

  • Ferric carboxymaltose因其應用範圍不斷擴大、性能優越、副作用較少、成本較低，在 2024 年佔據了靜脈鐵補充劑行業的主導地位。
  • 2024年，蔗糖鐵佔據了市場的大部分佔有率。嚴重過敏反應的發生率低提高了這些藥物的採用率。
  • 由於患有 CKD 和 CKD 相關缺鐵性貧血的患者數量不斷增加，預計慢性腎臟病領域將在 2024 年佔據最大佔有率。
  • 由於對輸液藥物的需求量大以及胃腸道疾病、癌症和 CKD 盛行率不斷上升，北美在 2024 年佔據了最大的區域佔有率。
  • 由於未滿足的需求不斷成長、醫療保健成本不斷上升以及現有全球參與者在當地的存在，預計亞太地區將在估計和預測期內以最快的速度成長。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 靜脈鐵市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章靜脈注射鐵市場：依產品分類的業務分析

  • 2024 年及 2030 年各產品市場佔有率
  • 產品細分細分儀表板
  • 市場規模、預測與趨勢分析（按產品，2018-2030 年）
  • 聚葡萄糖鐵
  • 蔗糖鐵
  • 羧基Carboxymaltose鐵
  • 其他

第5章靜脈鐵市場：應用商業分析

  • 2024 年及 2030 年各應用領域的市場佔有率
  • 應用程式細分儀表板
  • 市場規模、預測與趨勢分析（按應用，2018-2030 年）
  • 慢性腎臟病
  • 發炎性腸道疾病
  • 癌症
  • 其他疾病

第6章靜脈鐵製劑市場：按地區估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • AbbVie Inc.
    • AMAG Pharmaceuticals（Covis Pharma）
    • Daiichi Sankyo Company, Ltd.
    • Sanofi
    • Vifor Pharma Management Ltd.（CSL）
    • PHARMACOSMOS A/S
    • Zydus Group
    • Rockwell Medical, Inc.
Product Code: GVR-4-68038-000-2

Intravenous Iron Drugs Market Growth & Trends:

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights:

  • Ferric carboxymaltose dominated the intravenous iron drugs industry in 2024 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost.
  • Iron sucrose held a significant share of the market in 2024. A low rate of severe allergic reactions has increased the adoption rate of these drugs.
  • The chronic kidney disease segment held the largest share in 2024, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases.
  • North America held the largest regional share in 2024 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD.
  • Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Intravenous Iron Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Intravenous Iron Drugs Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Iron Dextran
    • 4.4.1. Iron Dextran Market, 2018 - 2030 (USD Million)
  • 4.5. Iron Sucrose
    • 4.5.1. Iron Sucrose Market, 2018 - 2030 (USD Million)
  • 4.6. Ferric Carboxymaltose
    • 4.6.1. Ferric Carboxymaltose Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Intravenous Iron Drugs Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Chronic Kidney Disease
    • 5.4.1. Chronic Kidney Diseases Market, 2018 - 2030 (USD Million)
  • 5.5. Inflammatory Bowel Disease
    • 5.5.1. Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market, 2018 - 2030 (USD Million)
  • 5.7. Other Diseases
    • 5.7.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 6. Intravenous Iron Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Intravenous Iron Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AMAG Pharmaceuticals (Covis Pharma)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Daiichi Sankyo Company, Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Vifor Pharma Management Ltd. (CSL)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. PHARMACOSMOS A/S
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Zydus Group
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Rockwell Medical, Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global intravenous iron drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 U.S. intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 13 Mexico intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Mexico intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 22 France intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 France intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 24 Italy intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Italy intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 26 Spain intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Spain intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 28 Norway intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Norway intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 31 Denmark intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 32 Sweden intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 Sweden intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 37 Japan intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 39 China intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 40 China intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 41 India intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 42 India intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 43 Australia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 44 Australia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 45 South Korea intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 46 South Korea intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 47 Thailand intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 48 Thailand intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 49 Latin America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 51 Latin America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 52 Brazil intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 53 Brazil intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 54 Argentina intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 55 Argentina intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 59 South Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 60 South Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 63 UAE intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 64 UAE intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait intravenous iron drugs market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Intravenous iron drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Intravenous iron drugs market dynamics
  • Fig. 12 Intravenous iron drugs market: Porter's five forces analysis
  • Fig. 13 Intravenous iron drugs market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Iron Dextran market, 2018 - 2030 (USD Million)
  • Fig. 16 Iron Sucrose market, 2018 - 2030 (USD Million)
  • Fig. 17 Ferric Carboxymaltose market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 Application market, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic kidney disease market, 2018 - 2030 (USD Million)
  • Fig. 21 Inflammatory bowel disease market, 2018 - 2030 (USD Million)
  • Fig. 22 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Other Diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Intravenous iron drugs market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 68 MEA intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework